Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaniaga BhdXKLS:7081 +1.75%68 Return-on-Tangible-Asset is 2.21% as of Jun. 2026, which is 21% below its 10-year median of 2.78. GuruFocus rates XKLS:7081 with a GF Score™ of 68/100 and a GF Value™ of RM1.16 (Fairly Valued). The stock has 6 warning signs investors should review. Among 122 Medical Distribution companies, Pharmaniaga Bhd ranks better than 52.46% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Pharmaniaga Bhd's annualizedNet Income for the quarter that ended in Jun. 2026 was RM50 Mil. Pharmaniaga Bhd's average total tangible assets for the quarter that ended in Jun. 2026 was RM2,266 Mil. Therefore, Pharmaniaga Bhd's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 2.21%.
The historical rank and industry rank for Pharmaniaga Bhd's Return-on-Tangible-Asset or its related term are showing as below:
XKLS:7081'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -33.72 Med: 2.78 Max: 10.05
Current: 2.71
During the past 13 years, Pharmaniaga Bhd's highest Return-on-Tangible-Asset was 10.05%. The lowest was -33.72%. And the median was 2.78%.
XKLS:7081's Return-on-Tangible-Asset is ranked better than 52.46% of 122
companies
in the Medical Distribution industry
Industry Median: 2.58
vs XKLS:7081: 2.71
Pharmaniaga Bhd (XKLS:7081) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Pharmaniaga Bhd Return-on-Tangible-Asset Related Terms
Pharmaniaga Bhd Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Pharmaniaga Bhd's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7081 vs MCK, COR, CAH: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Pharmaniaga Bhd's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaniaga Bhd Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Pharmaniaga Bhd's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Pharmaniaga Bhd's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 2.21% mean?
Pharmaniaga Bhd (XKLS:7081) has a Return-on-Tangible-Asset of 2.21% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pharmaniaga Bhd and its competitors. This is 21% below median its historical median of 2.78. According to the industry distribution chart, Pharmaniaga Bhd ranks #58 out of 122 companies in the Medical Distribution industry, placing it in the top 47.5%.
Is Pharmaniaga Bhd's Return-on-Tangible-Asset too high?
Pharmaniaga Bhd's current Return-on-Tangible-Asset of 2.21% is 21% below median its 10-year median of 2.78. The Medical Distribution industry median Return-on-Tangible-Asset is 2.58. Pharmaniaga Bhd's value of 2.21% is 14.3% below this industry median. Based on the distribution chart, Pharmaniaga Bhd ranks #58 out of 122 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Pharmaniaga Bhd has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's Return-on-Tangible-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Pharmaniaga Bhd ranks #58 out of 122 companies for Return-on-Tangible-Asset. This puts Pharmaniaga Bhd in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.58. Pharmaniaga Bhd's value of 2.21% is 14.3% below this benchmark. While the company's 10-year median is 2.78 vs. the industry median of 2.58, Pharmaniaga Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.58, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaniaga Bhd's current Return-on-Tangible-Asset of 2.21% is 14.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pharmaniaga Bhd and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaniaga Bhd's current Return-on-Tangible-Asset is 2.21%, which is 21% below median its own 10-year median of 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Fairly Valued. The stock's GF Value™ is RM1.16, compared to a current price of RM1.16 — trading right at its estimated fair value. The current Return-on-Tangible-Asset is 2.21%, which is 21% below median its 10-year median of 2.78 and 14.3% below the Medical Distribution industry median of 2.58. Pharmaniaga Bhd's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current Return-on-Tangible-Asset is 2.21% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be undervalued.
The current stock price of RM1.16 is trading 0% below its estimated GF Value™ of RM1.16.
GuruFocus considers Pharmaniaga Bhd to be Fairly Valued.
Key valuation signals for XKLS:7081:
Return-on-Tangible-Asset: 2.21% (21% below median its 10-year median of 2.78)
GF Value™: RM1.16 vs. price of RM1.16 (0% below fair value)
Industry Position: 14.3% below the Medical Distribution median (#58 of 122)
No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
68GF Score
Get the complete analysis for XKLS:7081
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7081 has been successfully added to your 
